Table 3. Platelet surface expression of P-selectin and activated GPIIb/IIIa, MPA formation and risk of death in 62 cancer patients.

Analyses of baseline levels as well as Landmark analyses of updated measurements at two months after study inclusion and analyses of the most recently measured values are given. Hazard ratios (HR) and 95 % confidence intervals (CI) for the increase per decile in each parameter are given.

	Activated via	Pre-chemotherapy value		Value measured 2 months after inclusion		Most recently measured value
		HR (95 % CI)	P-value	HR (95 % CI)	P-value	HR (95 % CI)	P-value
P-selectin (%)	-	0.88 (0.78–1.00)	0.046	0.88 (0.77–1.00)	0.050	0.94 (0.84–1.06)	0.304
	PAR-1	0.87 (0.77–0.98)	0.027	0.93 (0.82–1.05)	0.232	0.94 (0.83–1.05)	0.270
	PAR-4	0.83 (0.73–0.95)	0.007	0.85 (0.74–0.97)	0.015	0.87 (0.76–0.99)	0.041
	GPVI	0.84 (0.74–0.96)	0.011	0.89 (0.77–1.01)	0.078	0.89 (0.78–1.00)	0.056
Activated GPIIb/IIIa (%)	-	0.83 (0.73–0.95)	0.007	0.94 (0.82–1.07)	0.345	1.00 (0.89–1.12)	0.981
	PAR-1	0.89 (0.78–1.01)	0.067	1.02 (0.90–1.17)	0.730	0.97 (0.86–1.11)	0.681
	PAR-4	0.82 (0.72–0.94)	0.004	0.85 (0.75–0.98)	0.019	0.85 (0.74–0.98)	0.025
	GPVI	0.84 (0.73–0.97)	0.015	0.92 (0.81–1.06)	0.235	0.90 (0.79–1.02)	0.092
MPA (%)	-	1.02 (0.90–1.14)	0.811	1.04 (0.92–1.17)	0.585	1.10 (0.97–1.25)	0.160
	PAR-1	0.96 (0.85–1.09)	0.563	1.05 (0.93–1.19)	0.451	1.06 (0.94–1.19)	0.383
	PAR-4	1.00 (0.88–1.13)	0.951	1.03 (0.92–1.17)	0.598	1.06 (0.94–1.21)	0.331
	GPVI	1.01 (0.89–1.14)	0.927	0.96 (0.85–1.09)	0.559	1.05 (0.93–1.19)	0.415

PAR: protease-activated receptor; GP: glycoprotein; MPA: monocyte-platelet aggregates.